BioCryst Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 669.41, 725.96, 830.25, 986.65, 1179.17 ], "ebit_estimate": [ -428.65, 178.74, 245.97, 407.15, 571.07 ], "ebitda_estimate": [ -627.78, 85.62, null, null, null ], "net_income_estimate": [ -642.23, 132.22, 141.09, 241.26, 438.88 ], "per_share_eps_estimate": [ -2.55, 0.56, 0.66, 0.97, 1.61 ], "eps_nri_estimate": [ -2.55, 0.52, 0.54, 0.9, 1.43 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 0.57, 1.53, null, null, null ], "pretax_income_estimate": [ -445.22, 150.51, 171.24, 310.01, 551 ], "operating_cash_flow_per_share_estimate": [ 0.92, 1.03, null, null, null ], "roa_estimate": [ 13.4, 14.1, null, null, null ], "roe_estimate": [ 237.1, 798.5, null, null, null ], "gross_margin_estimate": [ 97.83, 98.67, 96.5, 96.17, 96.17 ], "operating_cash_flow_estimate": [ 222.88, 249.53, null, null, null ], "pettm_estimate": [ 0, 18.69, 15.79, 10.77, 6.5 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "9.47", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 9.47, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 184.89, 165.25, 170.41, 162.69, 182.23, 188.2, 192.74 ], "ebit_estimate": [ 52.17, 27.17, 31.89, 47.34, 65.46, 72.91, 75.81 ], "ebitda_estimate": [ 20.17, 26.81, 28.23, null, null, null, null ], "net_income_estimate": [ 39.85, 17.34, 28.76, 20.92, 38.65, 45.89, 48.98 ], "per_share_eps_estimate": [ 0.12, 0.08, 0.12, 0.11, 0.18, 0.2, 0.21 ], "eps_nri_estimate": [ 0.13, 0.05, 0.12, 0.09, 0.16, 0.19, 0.2 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ 36.5, 15.37, 28.1, 31.5, 49.93, 57.55, 60.75 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 98.27, 98.33, 98.03, 99, 99, 99, 99 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 24.08, 21.41, 17.1, 14.99, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "9.47", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 9.47, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }